Arjun V. Balar, MD
Immunotherapy has been shown to have an additional benefit when combined with other regimens for the treatment of patients with bladder cancer, according to Arjun Balar, MD.
, Balar, an assistant professor in the Department of Medicine, and director, Genitourinary Medical Oncology Program, NYU Langone’s Perlmutter Cancer Center, discussed novel immunotherapy combinations for the treatment of patients with bladder cancer.
OncLive: What is the status of immunotherapies and what are we looking forward to in the future?
Balar: There are several different ways of addressing the immune system in bladder cancer that are being tested in multiple clinical trials. One of the important pathways is the CTLA-4 pathway. There are early phase studies suggesting that the combination may lead to higher response rates and perhaps these responses might be durable.
... to read the full story